Comparative Pharmacology
Head-to-head clinical analysis: EFIDAC 24 CHLORPHENIRAMINE MALEATE versus PROMETHAZINE VC PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFIDAC 24 CHLORPHENIRAMINE MALEATE versus PROMETHAZINE VC PLAIN.
EFIDAC 24 CHLORPHENIRAMINE MALEATE vs PROMETHAZINE VC PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpheniramine maleate is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated allergic reactions. It also has anticholinergic and sedative properties due to central H1 receptor blockade.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
4 mg orally every 4-6 hours; maximum 24 mg/day.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
None Documented
None Documented
Terminal elimination half-life ranges from 14 to 25 hours (mean 20 hours) in adults; prolonged in hepatic or renal impairment (up to 50-60 hours in cirrhosis).
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with about 20-30% excreted via feces (biliary).
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic